On June 10, 2022, the International Department of the China Securities Regulatory Commission disclosedShandong Weigao Blood Purification Products Co., Ltd(hereafter referred to as”Weigao blood purification”) “Approval of the overseas initial public offering of shares of a limited company limited by shares (including common shares, preferred shares, etc., and forms derived from shares)” submitted.

Once accepted, it meansWeigao blood purificationGet a “path” or be able to submit a prospectus on the Hong Kong Stock Exchange soon.

Earlier, there were foreign media reports,Weigao blood purificationHuaxing Capital, Huatai Securities, and Citibank have been selected as their co-sponsors. They will submit listing applications as soon as this month, with plans to raise 500 million US dollars.
According toWeigao Co., Ltd.The (01066.HK) annual report shows thatWeigao blood purificationIn 2021, revenue was RMB 3,079 million and net profit was RMB 249 million. Currently, Weigao Co., Ltd. holds a total of 28.0871% of Weihai Weigao Blood Purification's shares.

Weigao blood purificationEstablished in 2004, it focuses on the field of blood purification, has about 5,100 employees, and serves more than 5,000 domestic customers. The group has seven subsidiaries and joins hands with two major international medical companies, Termau and Japanese Machinery. With the three major businesses of hemodialysis, peritoneal dialysis and dialysis services as the strategic development direction, it has achieved coverage of the entire industry chain of products and services related to blood purification treatment, and wholeheartedly serves patients with kidney disease around the world.

Weigao Group was founded in 1988 and is ranked among the top 500 in China with about 30,000 employees worldwide. It is under the control of 12 industrial groups and more than 80 subsidiaries of medical products, blood purification, orthopedics, medical equipment, pharmaceuticals, cardiac consumables, medical commerce, Shengji, Puri, blood technology, and surgical robots.

According to the Tianyan inspection information,Weigao blood purificationOther shareholders include Weigao Group holding 57.5317% of the shares, Weihai Kaide Information Technology Center holding 11.38529% of the shares, and Nichiki Equipment Co., Ltd. holding 2.99594% of the shares.

Copyright Notice: All original articles by Ryan Capital Ryanben Capital must be reprinted, and the source, author, and WeChat ID must be indicated at the beginning/end of the article. Otherwise, Ryan will be held legally responsible. Some articles were not able to get in touch with the original author or public account platform when they were promoted. For copyright issues, please contact the original author. More Hong Kong IPO listing information: www.ryanbencapital.com